NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 3,318 Shares of Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 3,318 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $6.97, for a total transaction of $23,126.46. Following the completion of the transaction, the insider now owns 5,550,771 shares of the company’s stock, valued at $38,688,873.87. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The shares were sold at an average price of $6.57, for a total transaction of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total value of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total value of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total transaction of $32,700.60.

NeuroPace Trading Up 1.3 %

NASDAQ:NPCE opened at $6.47 on Friday. The firm has a market capitalization of $186.13 million, a P/E ratio of -5.44 and a beta of 1.78. NeuroPace, Inc. has a 52 week low of $5.73 and a 52 week high of $18.15. The company has a quick ratio of 5.47, a current ratio of 6.37 and a debt-to-equity ratio of 5.97. The company has a fifty day moving average of $7.05 and a 200 day moving average of $8.41.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.03. The firm had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative net margin of 41.63% and a negative return on equity of 195.26%. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.36) earnings per share. On average, research analysts predict that NeuroPace, Inc. will post -1.08 earnings per share for the current year.

Institutional Investors Weigh In On NeuroPace

Several institutional investors and hedge funds have recently bought and sold shares of NPCE. Millennium Management LLC increased its stake in shares of NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after buying an additional 80,324 shares during the period. Vanguard Group Inc. boosted its holdings in NeuroPace by 18.3% in the first quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after acquiring an additional 75,512 shares in the last quarter. Acadian Asset Management LLC increased its position in NeuroPace by 46.0% during the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after purchasing an additional 21,703 shares during the period. Bank of New York Mellon Corp bought a new position in NeuroPace in the 2nd quarter worth $257,000. Finally, XTX Topco Ltd lifted its position in shares of NeuroPace by 56.1% in the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after purchasing an additional 8,643 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on NPCE shares. Morgan Stanley cut their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 target price on shares of NeuroPace in a report on Wednesday, August 14th. Finally, Wells Fargo & Company lowered their price target on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.